Simnotrelvir/ritonavir

Simnotrelvir/ritonavir, sold under the trade name Xiannuoxin, is a pharmaceutical combination used for the treatment of COVID-19. It combines simnotrelvir, an inhibitor of the SARS-CoV-2 3CL protease, with ritonavir, which inhibits the CYP3A enzyme. It was developed by Simcere Pharmaceutical and conditionally approved in China by the National Medical Products Administration in January 2023. Phase Ib trial results are available, and in a phase II/III trial it reduced the duration of symptoms by a median of 36 hours compared with placebo. This entry records what the source lead states and is not medical advice.